KLRC1 and COVID-19: Other investigators have reported that NKG2A is elevated in more severe COVID-19 cases and that utilizing NKG2A blockade can enhance cytotoxicity of patient-derived NK cells in genetically modified spike protein-expressing cell models (12, 13).